Mapsepicin-50 Injection 1's is an anti-cancer medicine that is used in conjunction with other drugs to treat breast cancer in people who have had tumor removal surgery. Mapsepicin-50 Injection 1's is used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer (abnormal growth in the cells of the breast).

Mapsepicin-50 Injection 1's contains Epirubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis.

Mapsepicin-50 Injection 1's may cause certain side effects such as nausea, headache, abdominal pain, loss of appetite, vomiting, dizziness, mouth sores, tiredness, back pain, diarrhoea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Mapsepicin-50 Injection 1's. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Mapsepicin-50 Injection 1's should be avoided if you are allergic to it. It is contraindicated in patients having a recent history of myocardial infarction (MI) or heart attack, patients with baseline neutrophil count < 1500 cells/mm3, severe arrhythmias, previous treatment with anthracyclines, and severe hepatic dysfunction. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any medicines such as cardiotoxic drugs (eg, Thalidomide, doxorubicin, Abiraterone, tamoxifen, letrozole), and cimetidine, as it can cause serious adverse effects. Mapsepicin-50 Injection 1's is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Mapsepicin-50 Injection 1's is not recommended for children as it is known to cause anthracycline-induced acute manifestations of cardiotoxicity and chronic CHF.

Mapsepicin-50 Injection 1's contains Epirubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis. It is used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer.

Mapsepicin-50 Injection 1's should be avoided if you are allergic to it. It is contraindicated in patients having a recent history of myocardial infarction (MI) or heart attack, patients with baseline neutrophil count < 1500 cells/mm3, severe arrhythmias, previous treatment with anthracyclines and severe hepatic dysfunction. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any medicines such as cardiotoxic drugs (e.g., Thalidomide, doxorubicin, Abiraterone, tamoxifen, letrozole), and cimetidine, as it can cause serious adverse effects. Mapsepicin-50 Injection 1's is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Mapsepicin-50 Injection 1's is not recommended for children as it is known to cause anthracycline-induced acute manifestations of cardiotoxicity and chronic CHF. Do not stop receiving Mapsepicin-50 Injection 1's without a doctor’s advice, as it can cause serious health conditions. Mapsepicin-50 Injection 1's is known to cause severe life-threatening haematological reactions, tissue necrosis, cardiomyopathy, secondary acute myelogenous leukaemia, and severe myelosuppression in some patients. Hence careful monitoring of the patient is needed while receiving the medicine.